Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

Fig. 3

Progression-free survival of Palbociclib plus endocrine therapy stratified by patient characteristics. (A) All patients; (B) Treatment-line settings; (C) Sensitivity to the most recent ET; (D)Performance status; (E) Number of metastatic sites; (F) Presence of visceral metastasis; (G) Metastatic tumors involving liver; (H) Metastatic tumors involving brain; (I) Only bone metastases; (J) Whether or not receiving chemotherapy for MBC; (K) Whether or not receiving ET for MBC; (L) Type of concomitant ET. Kaplan-Meier method and compared by the log-rank test. P-values of less than 0.05 indicate statistical significance. PFS, Progression-free survival; HR, Hazard ratio; CI, Confidence interval; NA, Not available; CHT, Chemotherapy; MBC, Metastatic breast cancer; ET, Endocrine therapy; FULV, Fulvestrant; AI, Aromatase Inhibitors

Back to article page